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ABSTRACTS
Smoking and drinking habits in 
relation to prostate cancer
J.WJ. van der Gulden, A.L. M. 
Verbeek and J.J. Kolk
Department of Occupational Medi­
cine, University of Nijmegen, The Neth­
erlands
British Journal of Urology (1994), 
73:382-389
Objective To evaluate the role of to­
bacco and alcohol consumption in the 
aetiology of prostate cancer.
Patients and Methods In a case-con- 
trol study conducted in the Netherlands, 
information on smoking and drinking 
habits was obtained from questionnaires 
completed by 345 patients exhibiting pri­
mary prostate cancer and by 1346 controls 
with benign prostate hyperplasia. The 
response rate was 79%.
Results No association was ob­
served between drinking habits and the 
risk of prostate cancer (324 cases versus 
1237 controls; odds ratio 1.36; 95%CI
0.84-2.22). A significantly elevated odds 
ratio was found for individuals who had 
smoked at any time during their lives (329 
cases versus 1212 controls; odds ratio 
2.12; 95%CI 1.24-3.62). However, no re­
lationship was observed between the num­
ber of cigarettes smoked, the duration of 
smoking, the age at which the subjects 
started smoking or with the calendar pe­
riod in which they were born. Odds ra­
tios calculated for individuals who 
smoked in consecutive 5-year periods be­
tween 1940 and 1989 did not show any 
trend. Furthermore, the risk of prostate 
cancer among ex-smokers did not differ 
significantly from the risk among current 
smokers, even when smoking was stopped 
more than 25 years previously.
Conclusion From these findings, 
which do not point to the causative agent, 
it would appear that neither smoking nor 
alcohol consumption seriously increases 
the risk of prostate cancer. (Reproduced 
with permission of Blackwell Science Ltd.)
International Comparison on ras 
Gene Mutations in Latent Prostate 
Carcinoma
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À.M.Y. Nomura and G.N. Stemmermann 
M. Watanabe, Department of Pathol­
ogy, Mie University School of Medicine, 
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Int. J; Cancer 58:174-178 (1994) 
Latent carcinomas of the prostate,
discovered at autopsy in men with no prior 
treatment for pro static disease, were stud­
ied for ras proto-oncogene mutations. 
Subjects included 21 Japanese, 15 U.S. 
whites, 15 U.S. blacks, 20 Hawaiian Japa­
nese and 10 Colombians. PCR and se­
quence-specific oligonucleotide hybrid­
ization identified mutations in 5 Japanese, 
in 1 Hawaiian Japanese, in 1 U.S. black, 
in 1 U.S. white and in 3 Colombians. The 
5 Japanese tumor samples contained 3 
point mutations in condon 12 of K-ras and
2 mutations in condon 12 ofN-JUs respec­
tively. One tumor in a Hawaiian Japanese 
man also showed aK-ras point mutation 
at condon 12. Two Colombians and one 
U.S. black man had tumors with mutations 
at codon 61 of H-ras, while 1 Colombian 
showed an N-ras mutation at this condon. 
The overall frequency of ras gene muta­
tions was low, but point mutations in 
condon 12 were most common in latent 
tumors of Japanese, who experienced the 
lowest incidence and mortality from this 
tumor, Latent tumors in men from ethnic 
groups with high mortality and incidence 
rates showed fewer ras mutations than the 
Japanese, and these were more likely to 
involve condon 61, This finding is con­
sistent with prior studies of more aggres­
sive clinical cancers in Japanese men that 
indicated a higher frequency of mutations 
at codon 61, (Reproduced with permission 
of John Wiley & Sons, Inc.)
Aneuploidy and Aneusomy of 
Chromosome 7 Detected fay 
Fluorescence in Situ Hybridization 
are Markers of Poor Prognosis in 
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Fluorescence in situ hybridization is 
a new methodology which can be used to 
detect cytogenetic anomalies within inter­
phase tumor cells. We used this technique 
to identify nonrandom numeric chromo­
somal alterations in tumor specimens from 
the poorest prognosis patients with patho­
logical stages T2N0MQand T3N0M0 pros­
tate carcinomas. Among 1368 patients 
treated by radical prostatectomy, 25 study 
patients were ascertained who died most 
quickly from progressive prostate carci­
noma within 3 years of diagnosis and sur­
gery, Tumors from 25 control patients 
who survived for more than 5 years and 
who were matched for age, tumor histo­
logical grade, and pathological stage also 
were evaluated. The tumors from all 25 
(100%) poor prognosis patients and from
11 of 25 (44%) control patients were 
found to be aneuploid by fluorescence in 
situ hybridization (P<0.0001). Alter­
ations of chromosome 7 were observed in 
24 of the tumors (96%) from the poor 
prognosis patients versus 3 tumors (12%) 
from the control group (P<0.0001). 
Moreover, a characteristic aneuploidy pat­
tern with multiple abnormal chromosomes 
and a hypertetrasomic population was 
generally found in tumors from the poor 
prognosis patients. This preliminary 
study suggests that fluorescence in situ 
hybridization studies of prostate cancer 
specimens may help to identify those pa­
tients at highest risk for early cancer death. 
(Reproduced with permission of The 
American Association for Cancer Re­
searchInc.)
Prostate Cancer Mortality in the 
United States by Cohort Year of 
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A.W. Hsing and S.S. Devesa
A.W. Hsing, Epidemiology and Bio­
statistics Program, Division of Cancer 
Etiology, National Cancer Institute, EPN 
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Prostate cancer is the second leading 
cause of cancer death among United States 
men, with rates among blacks twice those 
among whites. Over time, mortality has 
increased among nonwhites but has 
changed little among whites. Earlier re­
ports have predicted that the rise among 
nonwhites would diminish because it ap­
peared that those born in the late 1800s 
were at highest risk. Based on 1950-1989 
United States mortality data and popula­
tions at risk estimated using census data, 
we assessed prostate cancer mortality 
trends over me in white, nonwhite, and 
black men.
From 1950-1954 to 1985-1989, age- 
adjusted prostate cancer mortality rates in­
creased slightly for whites (9%) but sub­
stantially for non whites (67%). Among 
whites, rates increased over time in men 
over age 80 years but remained constant 
for younger men. Among nonwhites, 
rates increased steeply in those above age 
74 years and slightly in the age group 65- 
74 years but declined in those under age 
65 years, with the rate of decrease much 
more rapid in those under 55. The pre­
dicted reduction in risk among nonwhite 
men born since 1900, reported in an ear­
lier study based on the mortality pattern 
through 1970, has not occurred because
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rates continued to increase among older 
nonwhites.
In summary, prostate cancer mortal­
ity rates are rising among older men and 
decreasing in nonwhite young men. 
While improved detection of the cancer 
may partly account for the trend, analyti­
cal studies are needed to investigate the 
reasons for the increase in prostate cancer 
mortality in older men, the decrease in 
nonwhite young men, and the increasing 
excess risk among blacks. (Reproduced 
with permission of The American Associa­
tion for Cancer Research, Inc.)
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Nuclear DNA ploidy has been shown 
to have an important prognostic associa­
tion for patients with adenocarcinoma of 
the prostate. Flow cytometry and static 
image analysis are ploidy methods that 
have been used in prostate carcinoma. 
Fluorescence in situ hybridization (FISH) 
using chromosome-specific probes can be 
used to evaluate the ploidy of interphase 
nuclei. In this study FISH was compared 
with flow cytometry and static image 
analysis in determining ploidy in paraf­
fin-embedded tissue form 34 prostatic 
adenocarcinomas. Ploidy status using 
FISH was determined by enumerating 
centromeres of two chromosomes (8 and 
12) by use of directly-labeled -satellite 
DNA probes in isolated whole nuclei ob­
tained by the Hedley technique. All three 
methods identified 11 of 34 cases as dip­
loid and 17 of 34 cases as nondiploid 
(82% concordance). Six cases were dis­
cordant; two cases had discrepant results 
by each method. Ploidy classification as 
determined by FISH had an 88% concor­
dance with ploidy classification by either
flow cytometry or static image analysis. 
In conclusion, FISH was found to be a 
sensitive method of ploidy analysis in iso­
lated paraffin-embedded nuclei from pros­
tate adenocarcinomas. When the chromo­
somes commonly involved in aneuploidy 
have been identified in prostate 
adenocarcinoma, FISH has the potential 
to provide greater sensitivity for aneup­
loidy detection compared with currently 
available methods. (Reproduced with per­
mission ofW.B. Saunders Company.)
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Rats
M. Pollard and P.H Luckert
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University of Notre Dame, Notre Dame, 
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Adenocarcinomas were induced in 
the pro state-seminal ves icle complex of 
Lubund-Wister (L-W) rats by a single IV 
inoculation of N-methyl-N-nitrosourea. 
This was followed by three slow-release
S.C. implants of testosterone propionate, 
each at intervals of 2 months. Small (0.5 
cm diameter) palpable tumors developed 
which enlarged during the following 
month to 3-4 cm diameter. At the latter 
stage, tumor cells spread via lymphatics 
to the lungs and/or by direct extension 
into the peritoneal cavity. Rats with small 
palpable tumors were inoculated IV with 
viable Bacillus Calmette-Guerin (BCG). 
One month later the rats were killed and 
examined. Untreated rats with large tu­
mors served as controls. Comparison of 
the two groups revealed that body weights 
and tumor sizes were similar and most of 
them had developed metastatic tumors in 
the peritoneal cavity. However, lung 
metastases were rare in the BCG-inocu­
lated rats compared to controls. Spleen 
and liver weights were significantly 
heavier in the BCG-treated rats. It is 
speculated that an intra-vascular 
mechanism(s), engendered by BCG, im­
mobilized the circulating tumor cells, but 
not those tumor cells that spread by di­
rect extension from the primary tumor into 
the peritoneal cavity. (Reproduced with 
permission o f  the publisher.)
Androgen signal transduction and 
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Bartsch
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In the prostate, androgen action af­
fects the growth of the gland, its morph ol- 
y, and regulation of protein expression. 
Endocrine therapy of non-organ-confined 
tumors is based on the androgen depen­
dence of the vast majority of prostatic car­
cinomas, Although initial response rates 
are high, this therapy is only temporarily 
effective. Critical molecular changes ul­
timately resulting in androgen indepen­
dence of tumor cells are unknown at this 
time. The androgen signal-transduction 
cascade and its central element, the andro­
gen receptors (AR), are possible targets 
for such changes. Immunohistological 
analysis using anti-AR antibodies has re­
vealed the presence of AR in a vast ma­
jority of therapy-responsive as well as 
therapy-unresponsive prostatic carcino­
mas, indicating that loss of AR expression 
is not the reason for androgen indepen­
dence. On the other hand, molecular-bi- 
ology studies have revealed qualitative 
and quantitative impairment of AR ex­
pression in prostatic tumor cell lines that 
represent very late stages of prostatic car­
cinoma development. Mutant ARs were 
detected in the prostatic tumor cell line 
LNCaP and in two specimens from pri­
mary prostatic tumors. The LNCaP mu­
tant AR as wel 1 as mutant AR715met, one 
of the mutant receptors detected in tumor 
tissue, show a gain of function as com­
pared with the wild-type receptor. In ad­
dition to androgens, the natural activators 
of the AR, the LNCaP receptor is activated 
also by progestagenic and estrogenic ste- 
roids and by the nonsteroidal 
antiandrogen flutamide. AR715met is 
activated by adrenal androgens and 
progesterone in addition to androgens. 
Although determination of the frequency 
of point mutations in late prostatic carci­
noma requires further investigation, these 
data imply that tumor progression in an 
androgen-ablated environment may be 
accompanied by aberrant AR activation. 
(Reproduced with permission of Springer- 
Verlag New York, Inc.)
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